Mechanism

PCSK9 Inhibitors

Alirocumab

cardiovascular prevention, in all type of patients

Alirocumab

Alirocumab

cardiovascular events by 13% fully demonstrated

Coronary event by 12% fully demonstrated

death from all causes as adverse event by 62% suggested

cardiovascular death as adverse event by 62% suggested

myocardial infarction as adverse event by 56% suggested

All cause death by 15% suggested

Endpoint	TE [95% CI]	p val	I2	n	k
death from all causes as adverse event	0.38 [0.15 0.96]	p=0.04	0	3735	5	ODYSSEY Long-Term, ODYSSEY Alternative, ODYSSEY HIGH FH , ODYSSEY COMBO, ODYSSEY COMBO II,
serious adverse events	0.98 [0.82 1.18]	p=1.00	0	3732	5	ODYSSEY Long-Term, ODYSSEY Alternative, ODYSSEY HIGH FH , ODYSSEY COMBO, ODYSSEY COMBO II,
cardiovascular events as adverse event	0.91 [0.61 1.36]	p=1.00	0	2341	1	ODYSSEY Long-Term,
neurological SAE	0.94 [0.62 1.43]	p=1.00	0	2341	1	ODYSSEY Long-Term,
Neurocognitive disorder	2.28 [0.77 6.77]	p=1.00	0	2341	1	ODYSSEY Long-Term,
Muscle-related adverse events	no data
cardiovascular death as adverse event	0.38 [0.18 0.77]	p=0.04	0	3735	5	ODYSSEY Long-Term, ODYSSEY Alternative, ODYSSEY HIGH FH , ODYSSEY COMBO, ODYSSEY COMBO II,
myocardial infarction as adverse event	0.44 [0.22 0.85]	p=0.04	0	2908	3	ODYSSEY Long-Term, ODYSSEY Alternative, ODYSSEY COMBO,
unstable angina as adverse death	no data
cardiovascular events	0.87 [0.81 0.94]	p=0.04	0	18924	1	ODYSSEY OUTCOMES,
Cardiovascular death	0.88 [0.74 1.05]	p=1.00	0	18924	1	ODYSSEY OUTCOMES,
myocardial infarction (fatal and non fatal)	no data
stroke (fatal and non fatal)	no data
Coronary event	0.88 [0.80 0.96]	p=0.04	0	18924	1	ODYSSEY OUTCOMES,
Coronary death	0.92 [0.76 1.11]	p=1.00	0	18924	1	ODYSSEY OUTCOMES,
Allergic reactions	1.06 [0.79 1.41]	p=1.00	0	2341	1	ODYSSEY Long-Term,
All cause death	0.85 [0.73 0.98]	p=0.04	0	18924	1	ODYSSEY OUTCOMES,

Trial	Studied treatment	Control	Patients
ODYSSEY Long-Term, 2015	alirocumab 150 mg as a 1-ml subcutaneous injection every 2 weeks for 78 weeks.	placebo	patients at high risk for cardiovascular events who had LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or more and were receiving treatment with statins at the maximum tolerated dose (the highest dose associated with an acceptable side-effect profile), with or without other lipid-lowering therapy
ODYSSEY Alternative,	Alirocumab 75 mg with potential up-titration to 150 mg Q2W	Ezetimibe 10 mg	statin-intolerant patients
ODYSSEY OUTCOMES, 2018	Alirocumab (on top intensive or maximum-tolerated statin therapy)	placebo	Post-ACS patients (1 to 12 months)with elevated levels of atherogenic lipoproteins despite intensive or maximum-tolerated statin therapy
ODYSSEY FH 1,	Alirocumab 75 mg with potential up-titration to 150 mg Q2W	Placebo	patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy
ODYSSEY FH 2,	Alirocumab 75 mg with potential up-titration to 150 mg Q2W	Placebo	patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy
ODYSSEY HIGH FH ,	Alirocumab 150 mg Q2W	Placebo	patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy
ODYSSEY COMBO,	Alirocumab 75 mg with potential up-titration to 150 mg Q2W	Placebo	high cardiovascular risk patients on maximally tolerated statin therapy
ODYSSEY COMBO II,	Alirocumab 75 mg with potential up-titration to 150 mg Q2W	Ezetimibe 10 mg	high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins

Evolocumab

cardiovascular prevention, in all type of patients

Evolocumab

Evolocumab

Evolocumab

cardiovascular events by 20% fully demonstrated

myocardial infarction (fatal and non fatal) by 27% suggested

stroke (fatal and non fatal) by 21% suggested